[go: up one dir, main page]

BRPI1012324A2 - sistema de distribuição de droga de liberação sustentada intraocular e métodos para tratar condições oculares - Google Patents

sistema de distribuição de droga de liberação sustentada intraocular e métodos para tratar condições oculares

Info

Publication number
BRPI1012324A2
BRPI1012324A2 BRPI1012324A BRPI1012324A BRPI1012324A2 BR PI1012324 A2 BRPI1012324 A2 BR PI1012324A2 BR PI1012324 A BRPI1012324 A BR PI1012324A BR PI1012324 A BRPI1012324 A BR PI1012324A BR PI1012324 A2 BRPI1012324 A2 BR PI1012324A2
Authority
BR
Brazil
Prior art keywords
methods
delivery system
drug delivery
sustained release
release drug
Prior art date
Application number
BRPI1012324A
Other languages
English (en)
Inventor
Alazar N Ghebremeskel
Hui Liu
James A Burke
Kun Xu
Lon T Spada
Marianne M Do
Michael R Robinson
Patrick M Hughes
Scott Whitcup
Werhner C Orilla
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI1012324A2 publication Critical patent/BRPI1012324A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1012324A 2009-03-25 2010-03-25 sistema de distribuição de droga de liberação sustentada intraocular e métodos para tratar condições oculares BRPI1012324A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/411,250 US20100247606A1 (en) 2009-03-25 2009-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions
PCT/US2010/028584 WO2010111449A1 (en) 2009-03-25 2010-03-25 Intraocular sustained release drug delivery systems and methods for treating ocular conditions

Publications (1)

Publication Number Publication Date
BRPI1012324A2 true BRPI1012324A2 (pt) 2016-03-15

Family

ID=42326990

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012324A BRPI1012324A2 (pt) 2009-03-25 2010-03-25 sistema de distribuição de droga de liberação sustentada intraocular e métodos para tratar condições oculares

Country Status (13)

Country Link
US (1) US20100247606A1 (pt)
EP (1) EP2411013B1 (pt)
JP (2) JP2012521997A (pt)
KR (4) KR20160120800A (pt)
CN (1) CN102497865A (pt)
AU (3) AU2010229891A1 (pt)
BR (1) BRPI1012324A2 (pt)
CA (1) CA2756065A1 (pt)
IL (1) IL215205A0 (pt)
MX (1) MX2011009901A (pt)
NZ (1) NZ595294A (pt)
RU (2) RU2532333C2 (pt)
WO (1) WO2010111449A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP2432420A4 (en) 2009-05-18 2018-01-10 Dose Medical Corporation Drug eluting ocular implant
DK2525776T3 (en) 2010-01-22 2016-02-08 Allergan Inc Intracameral implants WITH depot preparation
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
CA2794956C (en) 2010-04-03 2017-05-02 Praful Doshi Medical devices including medicaments and methods of making and using same
US20120022137A1 (en) * 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
US10272040B2 (en) 2010-08-12 2019-04-30 Nanyang Technological University Liposomal formulation for ocular drug delivery
WO2012024376A1 (en) * 2010-08-17 2012-02-23 Allergan, Inc. Ep2 or ep4 agonists for treating corneal haze
EP2654715B1 (en) 2010-11-24 2017-01-25 Dose Medical Corporation Drug eluting ocular implant
EP3967297A1 (en) 2011-04-29 2022-03-16 Allergan, Inc. Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
EP2567689A1 (en) * 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
EP2570402A1 (en) * 2011-09-16 2013-03-20 Fovea Pharmaceuticals Bi-aryl derivatives, their preparation and their therapeutic application
EP2623490A1 (en) * 2012-02-03 2013-08-07 Fovea Pharmaceuticals 2-(3-aminophenoxy)-acetic acid derivatives as EP2 receptor agonists for use in treatment of glaucoma
US9249085B2 (en) * 2011-09-16 2016-02-02 Fovea Pharmaceuticals Aniline derivatives, their preparation and their therapeutic application
TWI560172B (en) * 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
WO2014120866A1 (en) 2013-01-31 2014-08-07 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure or glaucoma
CN104055695B (zh) * 2013-03-22 2016-12-28 深圳市绿蛙生物科技有限公司 中药型快干消毒护手霜及其制备方法
WO2014165308A2 (en) * 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
CN105101962A (zh) 2013-04-12 2015-11-25 阿勒根公司 用于减脂的比马前列素、比马前列素类似物、前列腺酰胺和前列腺素的持续释放
WO2015066548A1 (en) 2013-10-31 2015-05-07 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
WO2015085251A1 (en) * 2013-12-06 2015-06-11 Envisia Therapeutics Inc. Intracameral implant for treatment of an ocular condition
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9981938B2 (en) 2014-05-12 2018-05-29 Allergan, Inc. Quaternary ammonium alkyl esters as stable prodrugs
CA2950187A1 (en) 2014-05-29 2015-12-03 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
CN105266952A (zh) * 2014-07-09 2016-01-27 首都医科大学附属北京同仁医院 一种抗青光眼手术中所用防术后结膜粘连的器材
KR102456032B1 (ko) * 2014-09-06 2022-10-18 인티그럴 바이오시스템스 엘엘씨 눈에서 지속적 약물 방출을 달성하기 위한 방법 및 생체적합성 조성물
US10434071B2 (en) 2014-12-18 2019-10-08 Dsm Ip Assets, B.V. Drug delivery system for delivery of acid sensitivity drugs
WO2016187426A1 (en) * 2015-05-19 2016-11-24 Amorphex Therapeutics Llc A device that delivers a sustained low-dose of a myopia-suppressing drug
AU2016276170B2 (en) * 2015-06-06 2021-08-05 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
EP3324944A4 (en) * 2015-07-23 2019-04-03 Aerie Pharmaceuticals, Inc. INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE
US9820954B2 (en) * 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017062770A1 (en) 2015-10-08 2017-04-13 Silverberg Noah Punctal plug and bioadhesives
GB201522441D0 (en) 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
CN109937025B (zh) 2016-04-20 2022-07-29 多斯医学公司 生物可吸收眼部药物的递送装置
WO2017210130A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
US12171869B2 (en) * 2016-09-23 2024-12-24 Incept, Llc Intracameral drug delivery depots
CN111050754A (zh) * 2017-07-17 2020-04-21 商福溪生技有限公司 用于递送活性剂的微粒制剂
RU2685499C1 (ru) * 2018-07-19 2019-04-18 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения прогрессирующей миопии у детей с выявленным привычно-избыточным напряжением аккомодации
WO2020047141A1 (en) * 2018-08-30 2020-03-05 Liu Yunxiang Ophthalmic injectable formulation preparing and oculopathy treating and preventing
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
MX2021009525A (es) * 2019-02-08 2021-09-08 Ohio State Innovation Foundation Sustitutos vitreos de liberacion de antioxidante y usos de los mismos.
BR112022015533A2 (pt) 2020-02-06 2022-09-27 Ocular Therapeutix Inc Composições e métodos para tratar doenças oculares
PL3884929T3 (pl) 2020-03-25 2023-10-09 Ocular Therapeutix, Inc. Wprowadzany do oka wszczep zawierający inhibitor kinazy tyrozynowej
EP4142664A4 (en) 2020-04-27 2024-05-29 Ocular Therapeutix, Inc. METHODS FOR TREATING ALLERGIC CONJUNCTIVITIS
EP4149400A4 (en) * 2020-05-15 2024-05-01 Georgia Tech Research Corporation METHODS AND COMPOSITIONS FOR REDUCING INTRAOCULAR PRESSURE
US12064376B2 (en) * 2020-06-03 2024-08-20 Glaukos Corporation Rho kinase inhibitor releasing implants and related methods of use
WO2022170112A1 (en) * 2021-02-05 2022-08-11 Jenivision Inc. Compositions and methods for periorbital administration of ep2 receptor agonists
CN113133431A (zh) * 2021-02-25 2021-07-20 中南大学 慢性高眼压合并长眼轴动物模型的建立方法、模型及应用
EP4583930A1 (en) 2023-04-11 2025-07-16 Ocular Therapeutix, Inc. Ocular implant comprising axitinib polymorph iv
WO2024243081A1 (en) * 2023-05-19 2024-11-28 The Trustees Of Columbia University In The City Of New York Treating elevated intraocular pressure with nicotinamide

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT252264B (de) * 1965-03-17 1967-02-10 Etapharm Chem Pharm Lab Ges M Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US3749776A (en) * 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US4403353A (en) * 1981-06-25 1983-09-13 Tennant Jerald L Anterior chamber implant lens
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US5585401A (en) * 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5612027A (en) * 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5972326A (en) * 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US7867186B2 (en) * 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
US20040193095A1 (en) * 2003-03-29 2004-09-30 Shadduck John H. Implants for treating ocular hypertension, methods of use and methods of fabrication
JP2007518804A (ja) * 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
CA2554424A1 (en) * 2004-01-26 2005-08-11 Control Delivery Systems, Inc. Controlled and sustained delivery of nucleic acid-based therapeutic agents
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
JP5197354B2 (ja) * 2005-03-10 2013-05-15 アラーガン インコーポレイテッド 治療薬としての置換ガンマラクタム
JP5745208B2 (ja) * 2005-10-18 2015-07-08 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療
US7585895B2 (en) * 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
KR20080082618A (ko) * 2005-12-16 2008-09-11 알콘, 인코퍼레이티드 Ａｌｋ5 조절제를 사용한 안압의 조절
US9084662B2 (en) * 2006-01-17 2015-07-21 Transcend Medical, Inc. Drug delivery treatment device
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US20080097335A1 (en) * 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
PT2049112E (pt) * 2006-08-07 2012-06-05 Bausch & Lomb Tratamento de infeções e suas sequelas com agonistas dos recetores dos glucocorticoides dissociados associados a agentes anti-infecciosos
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
AU2008208042B2 (en) * 2007-01-25 2014-02-27 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US11078262B2 (en) * 2007-04-30 2021-08-03 Allergan, Inc. High viscosity macromolecular compositions for treating ocular conditions
US7947732B2 (en) * 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
ES2432058T3 (es) * 2007-11-09 2013-11-29 Allergan, Inc. Ciclopentanos sustituidos que tienen actividad de prostaglandina
US20110152328A1 (en) * 2008-04-16 2011-06-23 Whitcup Scott M Combination Therapy For Glaucoma
EP2296621A1 (en) * 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
DK2525776T3 (en) * 2010-01-22 2016-02-08 Allergan Inc Intracameral implants WITH depot preparation

Also Published As

Publication number Publication date
RU2664686C2 (ru) 2018-08-21
EP2411013B1 (en) 2020-08-19
CA2756065A1 (en) 2010-09-30
AU2010229891A1 (en) 2011-10-20
KR20160120800A (ko) 2016-10-18
MX2011009901A (es) 2011-11-18
RU2532333C2 (ru) 2014-11-10
AU2018211329A1 (en) 2018-08-23
KR20180108883A (ko) 2018-10-04
JP2015007117A (ja) 2015-01-15
NZ595294A (en) 2013-11-29
KR20120006998A (ko) 2012-01-19
JP2012521997A (ja) 2012-09-20
US20100247606A1 (en) 2010-09-30
IL215205A0 (en) 2011-12-29
WO2010111449A1 (en) 2010-09-30
CN102497865A (zh) 2012-06-13
KR20170064556A (ko) 2017-06-09
RU2014133501A (ru) 2016-03-10
AU2016231616A1 (en) 2016-10-20
RU2011140433A (ru) 2013-04-27
EP2411013A1 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
BRPI1012324A2 (pt) sistema de distribuição de droga de liberação sustentada intraocular e métodos para tratar condições oculares
IL262376A (en) Method and system for drug delivery
BRPI1015947A2 (pt) dispositivos para distribuição de fármacos e sistemas e métodos relacionados
BR112012002604A2 (pt) sistemas e métodos para entrega de anúncios direcionada
BR112014012499A2 (pt) dispositivo de entrega e liberação para endoprótese
BR112014009817A2 (pt) sistema e método para identificação de doenças oftamológicas
BR112013029946A2 (pt) dispositivo para distribuição de medicamento e método de controlar o dispositivo
BR112013005330A2 (pt) sistema de distribuição de cateter para válvula stent
BR112012013589A2 (pt) dispositivo e método para envio de dois ou mais agentes de fármaco
BR112013002765A2 (pt) implante deflectível, sistema e métodos para implantação do mesmo
BRPI1014975A2 (pt) sistema de entrega de implante
EP2552349A4 (en) Device and method for intraocular drug delivery
BRPI1007466A2 (pt) conjugado de insulina cristalina, formulação de liberação prolongada, e, sistema de distribuição de bomba
BRPI1013399A2 (pt) sistema de entrega de fármaco intervencional e métodos associados
BR112012002981A2 (pt) sistema de liberação de fármaco oftálmico contendo fosfolipídio e colesterol.
BRPI1016147A2 (pt) sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino
BRPI1013002A2 (pt) sistemas e métodos para entrega de conteúdo
EP2509665A4 (en) METHOD OF NASAL IRRIGATION AND DRUG DELIVERY
BRPI1010950A2 (pt) método para preparação de emulsão carregada de fármaco.
BR112013020363A2 (pt) sistema de transferência e injeção de tecido
BRPI0917030A2 (pt) sistema de liberação de fármaco contendo progestina
BRPI0821876A8 (pt) sistemas e métodos para administração de medicação
BRPI0912252A2 (pt) dispositivos oftálmicos para liberação controlada de agentes ativos.
BR112013012818A2 (pt) módulo medicamentoso e sistema de administração de fármaco
BRPI0911666A2 (pt) sistema para cirurgia oftalmológica refrativa.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]